title: Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
authors.forename: D A
authors.initials: DA
authors.lastname: de Luis
authors.forename: R
authors.initials: R
authors.lastname: Aller
authors.forename: L
authors.initials: L
authors.lastname: Cuellar
authors.forename: C
authors.initials: C
authors.lastname: Terroba
authors.forename: H
authors.initials: H
authors.lastname: Ovalle
authors.forename: O
authors.initials: O
authors.lastname: Izaola
authors.forename: E
authors.initials: E
authors.lastname: Romero
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; D007336:Insulin, Isophane; C072379:repaglinide